We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Eyes Heart Risks Of Proposed Lundbeck Drug

Law360 (April 3, 2009, 12:00 AM EDT) -- Officials at the U.S. Food and Drug Administration have expressed concern about a risk of cardiac arrhythmia and death associated with Danish drugmaker H. Lundbeck A/S's proposed schizophrenia drug Serdolect.

When it meets on Tuesday, the FDA's Psychopharmacologic Drugs Advisory Committee is scheduled to discuss safety and efficacy issues associated with the drug, which was temporarily withdrawn from the European market due to concerns over cardiac risks a decade ago.

Lundbeck filed a new drug application for Serdolect in the U.S. in September 2008.

In a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.